Anna is an investment professional on the Life Sciences team, and focuses on identifying and evaluating new investment opportunities.
Anna joined Frazier Healthcare Partners in 2018, where she focuses on evaluating investment opportunities and creating new ventures in the life sciences area.
Prior to joining Frazier, Anna was a management consultant in L.E.K. Consulting’s life sciences practice. While at L.E.K., Anna advised leading biotechnology and pharmaceutical companies on strategic planning, M&A, R&D, and business development strategy. Previously, Anna was an entrepreneurial fellow at Flagship Pioneering and a business mentor for the National Science Foundation Innovation Corps program. In addition, she has been involved in several projects to commercialize technologies, including a targeted drug delivery device and a single molecule protein sequencing technology.
Anna received her Ph.D. in Systems Biology from Harvard University, where she was a National Science Foundation Graduate Research Fellow. Anna studied circadian rhythm, chromosomal stability, and carbon fixation for industrial biotechnology and therapeutic applications. Her research resulted in numerous publications in peer-reviewed journals, including Science and PLOS. Anna also holds an A.B. in Biochemical Sciences from Harvard College.